<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="15491"><DrugName>taberminogene vadenovec</DrugName><DrugNamesKey><Name id="42901206">Trinam</Name><Name id="42901201">taberminogene vadenovec</Name></DrugNamesKey><DrugSynonyms><Name><Value>EG-004, Ark Therapeutics</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VEGF D-based gene therapy, Ark</Value></Name><Name><Value>local adenoviral gene therapy (VEGF D), Ark Therapeutics</Value></Name><Name><Value>adenoviral gene therapy (VEGF D/EG-001), Ark Therapeutics</Value></Name><Name><Value>local liposomal gene therapy (VEGF-165), Ark Therapeutics/ Valentis</Value></Name><Name><Value>taberminogene vadenovec</Value><Types><Type>INN</Type></Types></Name><Name><Value>Trinam</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24948">Ark Therapeutics Group plc</CompanyOriginator><CompaniesSecondary><Company id="24948">Ark Therapeutics Group plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15491" type="Drug"><TargetEntity id="301839" type="siDrug">Taberminogene vadenovec</TargetEntity><TargetEntity id="301840" type="siDrug">EG-001</TargetEntity></SourceEntity><SourceEntity id="24948" type="Company"><TargetEntity id="4295897420" type="organizationId">Premier Veterinary Group PLC</TargetEntity></SourceEntity><SourceEntity id="330" type="ciIndication"><TargetEntity id="228" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="330">Restenosis</Indication></IndicationsSecondary><ActionsPrimary><Action id="22452">FIGF gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="2660">Vasoprotectant</Action><Action id="2667">Antiarteriosclerotic</Action><Action id="4780">Adenovirus based gene therapy</Action></ActionsSecondary><Technologies><Technology id="764">Local formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="62">Virus recombinant</Technology></Technologies><LastModificationDate>2017-08-17T11:46:56.000Z</LastModificationDate><ChangeDateLast>2013-03-18T00:00:00.000Z</ChangeDateLast><AddedDate>1997-07-14T16:56:14.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24948" linkType="Company"&gt;Ark Therapeutics&lt;/ulink&gt; (formerly Eurogene) was developing taberminogene vadenovec (Trinam; EG-004), a VEGF-D gene therapy utilizing an adenoviral vector and the company's biodegradable extravascular delivery collar (EG-001) plus &lt;ulink linkID="17254" linkType="Company"&gt;Crucell&lt;/ulink&gt;'s PER.C6 cell line, for the potential prevention of post-surgical development of blood clots and intimal hyperplasia [&lt;ulink linkID="254738" linkType="reference"&gt;254738&lt;/ulink&gt;], [&lt;ulink linkID="474197" linkType="reference"&gt;474197&lt;/ulink&gt;], [&lt;ulink linkID="981869" linkType="Reference"&gt;981869&lt;/ulink&gt;].In January 2009, enrollment began in a US phase III trial [&lt;ulink linkID="974838" linkType="Reference"&gt;974838&lt;/ulink&gt;], [&lt;ulink linkID="978039" linkType="Reference"&gt;978039&lt;/ulink&gt;]. However, in May 2010, the company converted this trial into a phase IIb trial, and planned to seek to outlicense the drug for phase III development [&lt;ulink linkID="1096251" linkType="Reference"&gt;1096251&lt;/ulink&gt;] and in September 2010, Ark decided that the costs associated with the development of the drug were not appropriate for a company of its size and that a partner or licensee should be sought to continue development [&lt;ulink linkID="1129546" linkType="Reference"&gt;1129546&lt;/ulink&gt;]. In March 2013, the company was sold to WKD Holding and all programs were presumed to be discontinued [&lt;ulink linkID="1392490" linkType="Reference"&gt;1392490&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As part of the program, the company  investigated several VEGF genes and a variety of vectors; Ark had conducted a phase I trial utilizing a liposomal vector (under license from Valentis) [&lt;ulink linkID="360683" linkType="reference"&gt;360683&lt;/ulink&gt;], before making the decision to take forward an adenoviral vector combination to the next stage of clinical development [&lt;ulink linkID="474197" linkType="Reference"&gt;474197&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt; In November 2000, taberminogene vadenovec was granted Orphan Drug status by the FDA for the prevention of intimal hyperplasia in certain vascular anastomoses [&lt;ulink linkID="391638" linkType="reference"&gt;391638&lt;/ulink&gt;].  In June 2008, Ark intended to apply for US Fast Track status for the drug [&lt;ulink linkID="912290" linkType="Reference"&gt;912290&lt;/ulink&gt;]. Fast Track status was granted in May 2009 [&lt;ulink linkID="1006128" linkType="Reference"&gt;1006128&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The EU&lt;/subtitle&gt;In March 2004, Ark expected first filing for EU marketing approval to occur in 2007 [&lt;ulink linkID="526113" linkType="reference"&gt;526113&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2004, taberminogene vadenovec received Orphan Drug status in Europe to prevent blood vessels blocking after vascular graft access surgery [&lt;ulink linkID="545178" linkType="reference"&gt;545178&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2007, the FDA cleared Ark to begin a pivotal phase III trial of the drug under an SPA. The single study would be acceptable for marketing approval. The 18-month, multicenter, randomized, controlled, US phase III study (&lt;ulink linkID="54500" linkType="Protocol"&gt;NCT00895479&lt;/ulink&gt;) would evaluate the safety and efficacy of taberminogene vadenovec in 250 end stage renal disease patients who require vascular access for hemodialysis. Individuals would receive 4 x 10(10) viral particles plus standard-of-care (SOC) or SOC alone. The primary endpoint would be time to graft failure [&lt;ulink linkID="757302" linkType="Reference"&gt;757302&lt;/ulink&gt;]. In May 2007,  Ark filed for approval with the US recombinant DNA advisory committee for final clearance to begin the trial. At that time, Ark expected to begin the study in mid-2007 [&lt;ulink linkID="790314" linkType="Reference"&gt;790314&lt;/ulink&gt;]. Later in May 2007, the committee cleared Ark to begin the trial [&lt;ulink linkID="798170" linkType="Reference"&gt;798170&lt;/ulink&gt;]. In November 2007, the company expected to begin enrollment in the trial in the first half of 2008 [&lt;ulink linkID="877215" linkType="Reference"&gt;877215&lt;/ulink&gt;]. In June 2008, the FDA approved Ark's SPA for a phase III trial of taberminogene vadenovec for patients with end stage renal disease, who required vascular access for hemodialysis. In the multicenter, randomized, controlled study, patients were to  receive taberminogene vadenovec (4 x 10(10) viral particles), plus standard care, or standard care alone, at the time of surgical placement of a graft. The primary endpoint was primary unassisted patency. Overall patency would also be measured and safety would be assessed by an independent data and safety monitoring board, which would also conduct a sample sizing analysis following the enrollment of 150 patients. By that time, the agency had also approved the company's IND   [&lt;ulink linkID="912290" linkType="Reference"&gt;912290&lt;/ulink&gt;].  In January 2009, the company began enrollment after it was approved by the FDA, following Ark's completion of a product release test relating to potency prior to treating patients  [&lt;ulink linkID="974838" linkType="Reference"&gt;974838&lt;/ulink&gt;], [&lt;ulink linkID="978039" linkType="Reference"&gt;978039&lt;/ulink&gt;]. The first patient was enrolled in May 2009 [&lt;ulink linkID="1011484" linkType="Reference"&gt;1011484&lt;/ulink&gt;]. By November 2009,   more test sites had been opened, so the rate of patient enrollment was expected to increase [&lt;ulink linkID="1056284" linkType="Reference"&gt;1056284&lt;/ulink&gt;]. In March 2010, Ark believed that initial data on the trial's primary endpoint could be available by the second half of that year [&lt;ulink linkID="1081206" linkType="Reference"&gt;1081206&lt;/ulink&gt;]. However, in May 2010, the company converted this trial into a phase IIb trial [&lt;ulink linkID="1096251" linkType="Reference"&gt;1096251&lt;/ulink&gt;]. In May 2010, data from the trial were expected in mid-2011 [&lt;ulink linkID="1100922" linkType="Reference"&gt;1100922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, data from an open-label, non-randomized, standard-care, controlled, phase II trial were reported. The data showed that the access grafts of patients treated taberminogene vadenovec had  almost three times the primary unassisted patency, compared with the grafts of controls. Overall patency data showed that taberminogene vadenovec treatment resulted in grafts remaining functional for dialysis for over three times as long as control grafts. The drug was well tolerated and no quantifiable systemic distribution of the product or serious side effects were seen [&lt;ulink linkID="912290" linkType="Reference"&gt;912290&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The ascending-dose, US phase II study, initiated in May 2004, was designed to examine the effects and safety of taberminogene vadenovec in intimal hyperplasia prevention in  up to 20 patients and was expected to complete within 12 months. This phase II trial forms the first part of the phase II/III study that had been approved [&lt;ulink linkID="545429" linkType="reference"&gt;545429&lt;/ulink&gt;]. By January 2005, five of the 20 patients had been enrolled [&lt;ulink linkID="580246" linkType="Reference"&gt;580246&lt;/ulink&gt;]; at that time,  initial results from the trial were expected at the end of 2005 [&lt;ulink linkID="580246" linkType="Reference"&gt;580246&lt;/ulink&gt;]. In July 2005, the company completed enrollment in the low-dose arm of the study and received FDA and Data Safety Monitoring Board approval to move to the higher dose phase. Preliminary results from the low-dose phase were scheduled to be presented later in 2005 [&lt;ulink linkID="613634" linkType="Reference"&gt;613634&lt;/ulink&gt;]. In October 2005, Ark reported interim data from the ongoing phase II trial. The open-label, standard care-controlled study had treated six   end-stage renal disease patients with one dose of 4 x10 9 particles. Treatment was given at the time of surgery to implant an access graft. After a year, no serious side effects were seen, although one patient withdrew from the study due to a surgery-related infection. The grafts remained functional at 14 months, compared to previous mean graft failure in these patients at 4.5 months. No systemic distribution of the VEGF gene was found [&lt;ulink linkID="629247" linkType="Reference"&gt;629247&lt;/ulink&gt;]. In August 2006, additional data from this trial were reported. Of the 16 patients included, six were assigned to a low dose group, receiving one dose of VEGF 4 x109 viral particles, delivered either when a new graft was implanted or when a replacement graft was inserted in a new place following a previous failure. A further six were assigned to a high dose group, receiving 4 x 1010 viral particles, while  the other four patients were assigned to a control group receiving standard care only. The access grafts of low dose patients remained functional for dialysis for over five times longer than control patients. All high dose patients with successful grafts still had open grafts with patency of 8 months on average at that time. No systemic distribution of taberminogene vadenovec was observed in the high or low dose groups and the product was well tolerated [&lt;ulink linkID="685884" linkType="Reference"&gt;685884&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2002, plans were underway to initiate a US phase II/III trial of the therapy [&lt;ulink linkID="446942" linkType="reference"&gt;446942&lt;/ulink&gt;], [&lt;ulink linkID="464111" linkType="reference"&gt;464111&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2000, a phase I trial of EG-001 and Valentis' VEGF-165 product (a plasmid encoding VEGF-165 and a cationic lipid-based gene delivery system; qv) was initiated to provide proof-of-principle for Ark's strategy. The trial, which was conducted at three university hospitals in Finland, was designed to demonstrate that the VEGF gene, delivered locally to the outside surface of a blood vessel, would transfect and express in the smooth muscle cells of the vessel wall [&lt;ulink linkID="360683" linkType="reference"&gt;360683&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In January 2007, Ark planned to initiate a preclinical study to investigate biodistribution in an end-to-side procedure for surgical placement of the graft. If results were positive, the procedure would be included in a phase III trial alongside the end-to-end procedure [&lt;ulink linkID="757302" linkType="Reference"&gt;757302&lt;/ulink&gt;]. By June 2008, the study had been conducted and the results were shown to be in line with those seen previously [&lt;ulink linkID="912290" linkType="Reference"&gt;912290&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2002, preclinical data on taberminogene vadenovec were presented at the SMi Gene Therapy conference in London, UK. In the rabbit carotid artery model, taberminogene vadenovec treatment resulted in no intimal hyperplasia compared to a control gene, and in a pig model, two of four grafts were at least 50% open after 28 days, with no toxicity observed [&lt;ulink linkID="443101" linkType="reference"&gt;443101&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The adenoviral vector used in EG-004 has independently been used in several gene trials and its safety profile has been well established [&lt;ulink linkID="474197" linkType="reference"&gt;474197&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, Ark had licensed use of a VEGF-D gene from &lt;ulink linkID="1020737" linkType="Company"&gt;Vegenics&lt;/ulink&gt; (originally licensed from the Ludwig Institute for Cancer Research) for taberminogene vadenovec. Vegenics would be entitled to royalties and milestone payments [&lt;ulink linkID="870678" linkType="Reference"&gt;870678&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2005, Ark was issued with a Hungarian patent for taberminogene vadenovec which could be maintained until 2017 [&lt;ulink linkID="599567" linkType="Reference"&gt;599567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, Ark Therapeutics was issued with a European patent for taberminogene vadenovec. Subject to the payment of renewal fees, this patent could be maintained until 2016 or longer [&lt;ulink linkID="581204" linkType="Reference"&gt;581204&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2000, Eurogene had entered into an agreement with Valentis whereby Valentis provided Eurogene assess to its proprietary DOTMA-based cationic lipid delivery system for a non-viral VEGF165 gene medicine [&lt;ulink linkID="360683" linkType="reference"&gt;360683&lt;/ulink&gt;], [&lt;ulink linkID="378897" linkType="reference"&gt;378897&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24948">Ark Therapeutics Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="330">Restenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-15T00:00:00.000Z</StatusDate><Source id="1392490" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24948">Ark Therapeutics Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="330">Restenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-09T00:00:00.000Z</StatusDate><Source id="1129546" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24948">Ark Therapeutics Group plc</Company><Country id="FI">Finland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="330">Restenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-03-24T00:00:00.000Z</StatusDate><Source id="360683" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24948">Ark Therapeutics Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="330">Restenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-07-14T00:00:00.000Z</StatusDate><Source id="254738" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24948">Ark Therapeutics Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="330">Restenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-08T00:00:00.000Z</StatusDate><Source id="974838" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24948">Ark Therapeutics Group plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="330">Restenosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-05-11T00:00:00.000Z</StatusDate><Source id="545429" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="24948">Ark Therapeutics Group plc</OwnerCompany><Country id="US">US</Country><Indication id="330">Restenosis</Indication><AwardedIndication>Treatment for the prevention of de novo stenosis at vascular surgical anastamoses</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-05T00:00:00.000Z</MileStoneDate><Source id="1006128" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="24948">Ark Therapeutics Group plc</OwnerCompany><Country id="US">US</Country><Indication id="330">Restenosis</Indication><AwardedIndication>Treatment for the prevention of de novo stenosis at vascular surgical anastamoses</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-02T00:00:00.000Z</MileStoneDate><Source id="912290" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="24948">Ark Therapeutics Group plc</OwnerCompany><Country id="US">US</Country><Indication id="330">Restenosis</Indication><AwardedIndication>Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-10-24T00:00:00.000Z</MileStoneDate><Source id="391638" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-03157"><Name>FIGF gene</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1017119">Urigen Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15504">Opthea Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21091">Ludwig Institute for Cancer Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="24948">Ark Therapeutics Group plc</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="29632">Licentia Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>4</CountActive><CountInactive>1</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="111406" title="Ark Therapeutics to apply Vegenics' VEGF-D gene for use in Trinam"></Deal><Deal id="116248" title="Eurogene to use Crucell's PER.C6 cell line in its research programs"></Deal><Deal id="125210" title="Eurogene to access Valentis' DOTMA-based cationic lipid delivery system "></Deal><Deal id="128462" title="Ark to acquire rights to apply Ludwig Institute for Cancer Research's VEGF IP "></Deal><Deal id="128464" title="Ark to acquire rights to apply Licentia's Institute for Cancer Research's VEGF IP"></Deal><Deal id="128465" title="Vegenics to acquire rights to Ludwig Institute for Cancer Research's VEGF IP"></Deal><Deal id="128466" title="Vegenics to acquire rights to Licentia's VEGF IP"></Deal></Deals><PatentFamilies><PatentFamily id="1726631" number="WO-00037025" title="Antibodies to truncated VEGF-D and uses thereof."></PatentFamily><PatentFamily id="1948212" number="WO-00024412" title="Use Of VEGF-C Or VEGF-D Gene Or Protein To Prevent Restenosis"></PatentFamily><PatentFamily id="769926" number="WO-03082918" title="VEGF peptides and their use"></PatentFamily><PatentFamily id="809313" number="WO-2007038056" title="Protease-resistant forms of VEGF-D, method of making and method of use"></PatentFamily><PatentFamily id="940846" number="WO-00152875" title="VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="R&amp;D Systems Inc" id="1003734"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PerkinElmer Inc" id="1019657"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eyecopharm AG" id="1035122"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Herantis Pharma Plc" id="1096867"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bio-Rad Laboratories Inc" id="14811"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Opthea Ltd" id="15504"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ludwig Institute for Cancer Research" id="21091"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ark Therapeutics Group plc" id="24948"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>4</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Licentia Ltd" id="29632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>